



Published on *Drug Pipeline* (<https://www.drugpipeline.net>)

Home > Uveitis Therapeutics in Asia-Pacific Markets to 2023 - Increasing Prevalence, Continued Uptake of Biologics and Novel Pipeline

Drugs to Drive the Market

Uveitis Therapeutics in Asia-Pacific Markets to 2023 - Increasing Prevalence, Continued Uptake of Biologics and Novel Pipeline Drugs to Drive the Market

Publication ID:

GBI0218002

Publication Date:

February 01, 2018

Pages:

91

Publisher:

GBI Research

Region:

Asia Pacific [1]

\$4,995.00

Publication License Type *

Single User License (PDF), \$4,995.00

Site License (PDF), \$9,990.00

Global License (PDF), \$14,985.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart



Description:

Uveitis Therapeutics in Asia-Pacific Markets to 2023 - Increasing Prevalence, Continued Uptake of Biologics and Novel Pipeline Drugs to Drive the Market

Summary

Uveitis refers to inflammation of the uvea, the middle vascular coat of the eye, comprising the iris, ciliary body, and choroid. It may also involve other adjacent tissues of the eye. Uveitis occurs at any age, but it most commonly affects individuals between 20 and 59 years of age. However, this trend is changing; the percentage of elderly uveitis patients has been increasing in recent years. Uveitis represents a major cause of ocular morbidity worldwide and often results in complications such as cataracts, glaucoma, ocular hypertension, macular issues, and retinal detachment.

It is a leading cause of blindness in both developed and developing countries and is the fifth most common cause of vision loss in the developed world. The uveitis market is characterized by a small selection of marketed drug options, consisting of corticosteroid therapies, immunosuppressive therapies and biologics. Historically, corticosteroid therapies have made up the bulk of the uveitis market.

Currently only one targeted therapy is available in the Asia-Pacific uveitis market, which is AbbVie's Humira (adalimumab). The late-stage uveitis pipeline is composed of Santen's Opsiria and Clearside Biomedical's CLS-TA, which are expected to be highly lucrative and address some of the unmet needs.

These new drugs will expand the options available to treat uveitis patients and contribute to overall market growth by offering novel treatment mechanisms, including new drug delivery routes and novel, non-corticosteroid drug molecules.

Scope

- The Asia-Pacific uveitis market will be valued at \$405.5m in 2023, growing from \$179m in 2016, at a compound annual growth rate of 12.4%.
- What are the key factors driving the Asia-Pacific uveitis treatment market?
- How will targeted therapies such as Humira contribute to growth?
- Do branded therapies show continuous growth, and are they facing competition from generics?
- How will branded therapies be affected by upcoming pipeline therapies?
- Corticosteroid therapies dominate the uveitis market, but unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs?
- What are the common targets and mechanisms of action of pipeline therapies?
- What are the commercial prospects for the most promising late-stage products?

- Various drivers and barriers will influence the market over the forecast period.
- What are the barriers that will limit the uptake of premium-priced therapies in the assessed countries?
- Which factors are most likely to drive the market in these countries?
- What licensing and co-development deals have occurred within this therapy area since 2006?

Reasons to buy

- Understand the current clinical and commercial landscape through a comprehensive analysis of disease symptoms, diagnostic methods, etiology, pathophysiology, epidemiology, prognosis and treatment.
- Visualize the composition of the uveitis market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
- Analyze the uveitis pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
- Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
- Predict uveitis market growth in the five assessed Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.
- Identify commercial opportunities in the uveitis deals landscape by analyzing trends in licensing and co-development deals.

Table Of Contents:

Table of Contents

1	Table of Contents	5
1.1	List of Tables	7
1.2	List of Figures	8
2	Introduction	9
2.1	Disease Introduction	9
2.2	Epidemiology	10
2.3	Symptoms	11
2.4	Etiology and Pathophysiology	11
2.4.1	Autoimmune uveitis	12
2.4.2	Non-autoimmune uveitis	12
2.5	Diagnosis	14
2.6	Prognosis	15
2.7	Treatment Options	16
2.7.1	Corticosteroids	17

2.7.2	Immunosuppressive Agents	18
2.7.3	Biologics	18
2.7.4	Adjuvant Therapy	19
3	Marketed Products	20
3.1	Overview	20
3.1.1	Humira (adalimumab) - AbbVie	21
3.1.2	Retisert (fluocinolone acetonide) - Bausch & Lomb	22
3.1.3	Ozurdex (dexamethasone) - Allergan	23
3.1.4	Neoral (Cyclosporine) - Novartis	25
3.1.5	Mycept (Mycophenolate mofetil) - Panacea Biotec	26
3.1.6	Medrol (Methylprednisolone) - Pfizer	27
3.1.7	Betamethasone - Merck & Co.	28
3.1.8	Pred Forte (Prednisolone) - Allergan	28
3.2	Comparative Efficacy and Safety of Marketed Products	29
4	Pipeline Analysis	32
4.1	Overview	32
4.2	Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type	33
4.3	Pipeline by Molecular Target	34
4.4	Promising Pipeline Candidates	36
4.4.1	DE-109/ Opsiria (Sirolimus) - Santen	36
4.4.2	CLS-TA (triamcinolone acetonide) - Clearside BioMedical	37
4.5	Heatmap for Pipeline Products	38
4.6	Product Competitiveness Framework	40
5	Clinical Trial Analysis	42
5.1	Failure Rate	42
5.1.1	Overall Failure Rate	42
5.1.2	Failure Rate by Phase and Molecule Type	43
5.1.3	Failure Rate by Phase and Molecular Target	44
5.2	Clinical Trial Size	45
5.2.1	Patient Enrollment per Product by Molecule Type and Stage of Development	45
5.2.2	Patient Enrollment per Product by Molecular Target and Stage of Development	46
5.2.3	Patient Enrollment per Trial by Molecule Type and Stage of Development	47
5.2.4	Patient Enrollment per Trial by Molecular Target and Stage of Development	48
5.3	Clinical Trial Duration	49
5.3.1	Trial Duration by Molecule Type and Stage of Development	49
5.3.2	Trial Duration by Molecular Target and Stage of Development	50
5.4	Summary of Clinical Trial Metrics	51
6	Multi-scenario Forecast	53
6.1	Geographical Markets	53
6.2	Asia-Pacific Market	53

6.2.1	Treatment Usage Patterns	53
6.2.2	Market Size	54
6.3	India	55
6.3.1	Treatment Usage Patterns	55
6.3.2	Annual Cost of Therapy	56
6.3.3	Market Size	57
6.4	China	58
6.4.1	Treatment Usage Patterns	58
6.4.2	Annual Cost of Therapy	59
6.4.3	Market Size	60
6.5	Australia	61
6.5.1	Treatment Usage Patterns	61
6.5.2	Annual Cost of Therapy	62
6.5.3	Market Size	63
6.6	South Korea	64
6.6.1	Treatment Usage Patterns	64
6.6.2	Annual Cost of Therapy	65
6.6.3	Market Size	66
6.7	Japan	67
6.7.1	Treatment Usage Patterns	67
6.7.2	Annual Cost of Therapy	68
6.7.3	Market Size	69
7	Drivers and Barriers	71
7.1	Drivers	71
7.1.1	Increasing Usage of Biologics	71
7.1.2	Promising Late-Stage Pipeline Products Can Change Treatment Paradigm	71
7.1.3	Increasing Elderly Population and Incidence of Uveitis	71
7.2	Barriers	71
7.2.1	Uveitis - An Under-Researched Disease	71
7.2.2	Low Diagnosis and Treatment Rates	72
7.2.3	Steep Prices of Therapeutics to Slow Down Market Growth	72
8	Deals and Strategic Consolidations	73
8.1	Licensing Deals	73
8.1.1	Deals by Region and Value	73
8.1.2	Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value	73
8.1.3	Deal Value by Stage of Development, Molecule Type, and Molecular Target	73
8.1.4	Key Licensing Deals	76
8.2	Co-development Deals	77
8.2.1	Deals by region, value, year, stage of development, molecule type and molecular target	77
8.2.2	Key Co-development Deals	77

9 Appendix 78

9.1 All Pipeline Drugs by Stage of Development 78

9.1.1 Discovery 78

9.1.2 Preclinical 78

9.1.3 IND/CTA-filed 79

9.1.4 Phase I 79

9.1.5 Phase II 80

9.1.6 Phase III 80

9.1.7 Pre-registration 80

9.2 Market Forecasts to 2023 81

9.2.1 Asia-Pacific 81

9.2.2 India 81

9.2.3 China 81

9.2.4 Australia 82

9.2.5 South Korea 82

9.2.6 Japan 83

9.3 Bibliography 83

9.4 Abbreviations 87

9.5 Research Methodology 88

9.5.1 Secondary Research 88

9.5.2 Marketed Product Profiles 88

9.5.3 Late-Stage Pipeline Candidates 88

9.5.4 Comparative Efficacy and Safety Heatmap for Marketed and Pipeline Products 88

9.5.5 Product Competitiveness Framework 89

9.5.6 Pipeline Analysis 89

9.5.7 Forecasting Model 90

9.5.8 Deals Data Analysis 91

9.6 Contact Us 91

9.7 Disclaimer 91

List of Tables

1.1 List of Tables

Table 1: Uveitis Therapeutics Market, APAC, Anatomic Classification of Uveitis 9

Table 2: Uveitis Therapeutics Market, APAC, Definition of Onset, Duration and Course of Uveitis 10

Table 3: Uveitis Therapeutics, APAC, Diseases Most Frequently Associated with Uveitis 13

Table 4: Uveitis Therapeutics, APAC, Investigations for Systemic Conditions Causing Uveitis 15

Table 5: Uveitis Therapeutics Market, APAC, Prognosis for Uveitis Patients 16

Table 6: Uveitis Therapeutics Market, Global, Licensing Deals with Disclosed Deal Value, 2006-2017 77

Table 7: Uveitis Therapeutics Market, Global, All Pipeline Products, Discovery, 2017 78

Table 8: Uveitis Therapeutics Market, Global, All Pipeline Products, Preclinical, 2017 78

Table 9: Uveitis Therapeutics Market, Global, All Pipeline Products, IND/CTA-filed, 2017	79
Table 10: Uveitis, Global, All Pipeline Products, Phase I, 2017	79
Table 11: Uveitis Therapeutics Market, Global, All Pipeline Products, Phase II, 2017	80
Table 12: Uveitis Therapeutics Market, Global, All Pipeline Products, Phase III, 2017	80
Table 13: Uveitis Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2017	80
Table 14: Uveitis Therapeutics Market, Asia-Pacific, Market Forecast, 2016-2023	81
Table 15: Uveitis Therapeutics Market, India, Market Forecast, 2016-2023	81
Table 16: Uveitis Therapeutics Market, China, Market Forecast, 2016-2023	81
Table 17: Uveitis Therapeutics Market, Australia, Market Forecast, 2016-2023	82
Table 18: Uveitis Therapeutics Market, South Korea, Market Forecast, 2016-2023	82
Table 19: Uveitis Therapeutics Market, Japan, Market Forecast, 2016-2023	83

List of Figures

1.2 List of Figures

Figure 1: Uveitis Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products for the Treatment of Uveitis	31
Figure 2: Uveitis Therapeutics Market, Global, Pipeline, 2017	34
Figure 3: Uveitis Therapeutics Market, Global, Pipeline by Molecular Target, 2017	35
Figure 4: Uveitis Therapeutics Market, APAC, DE-109/Opsiria Market (\$m), 2019-2023	37
Figure 5: Uveitis Market, Comparative Efficacy and Safety Heatmap for Pipeline Products	39
Figure 6: Uveitis Therapeutics Market, Competitor Matrix for Uveitis Marketed and Pipeline Products, 2017	40
Figure 7: Uveitis Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2006-2016	43
Figure 8: Uveitis Therapeutics, Global, Clinical Trial Failure Rates by Molecule Type (%), 2006-2016	44
Figure 9: Uveitis Therapeutics, Global, Clinical Trial Failure Rates by Molecular Target (%), 2006-2016	45
Figure 10: Uveitis Therapeutics, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006-2016	46
Figure 11: Uveitis Therapeutics, Global, Clinical Trial Size per Product by Molecular Target (participants), 2006-2016	47
Figure 12: Uveitis Therapeutics, Global, Clinical Trial Size per Trial by Molecule Type (participants), 2006-2016	48
Figure 13: Uveitis Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target (participants), 2006-2016	49
Figure 14: Uveitis Therapeutics, Global, Clinical Trial Duration by Molecule Type (months), 2006-2016	50
Figure 15: Uveitis Therapeutics, Global, Clinical Trial Duration by Molecular Target (months), 2006-2016	51
Figure 16: Uveitis Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type	52

Figure 17: Uveitis Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 52

Figure 18: Uveitis Therapeutics Market, APAC, Treatment Patterns ('000), 2016-2023 54

Figure 19: Uveitis Therapeutics Market, APAC, Market Size (\$m), 2016-2023 55

Figure 20: Uveitis Therapeutics Market, India, Treatment Patterns ('000), 2016-2023 56

Figure 21: Uveitis Therapeutics Market, India, Annual Cost of Therapy (\$), 2016-2023 57

Figure 22: Uveitis Therapeutics Market, India, Market Size (\$m), 2016-2023 58

Figure 23: Uveitis Therapeutics Market, China, Treatment Patterns ('000), 2016-2023 59

Figure 24: Uveitis Therapeutics Market, China, Annual Cost of Therapy (\$), 2016-2023 60

Figure 25: Uveitis Therapeutics Market, China, Market Size (\$m), 2016-2023 61

Figure 26: Uveitis Therapeutics Market, Australia, Treatment Patterns ('000), 2016-2023 62

Figure 27: Uveitis Therapeutics Market, Australia, Annual Cost of Therapy (\$), 2016-2023 63

Figure 28: Uveitis Therapeutics Market, Australia, Market Size (\$m), 2016-2023 64

Figure 29: Uveitis Therapeutics Market, South Korea, Treatment Patterns ('000), 2016-2023 65

Figure 30: Uveitis Therapeutics Market, South Korea, Annual Cost of Therapy (\$), 2016-2023 66

Figure 31: Uveitis Therapeutics Market, South Korea, Market Size (\$m), 2016-2023 67

Figure 32: Uveitis Therapeutics Market, Japan, Treatment Patterns ('000), 2016-2023 68

Figure 33: Uveitis Therapeutics Market, Japan, Annual Cost of Therapy (\$), 2016-2023 69

Figure 34: Uveitis Therapeutics Market, Japan, Market Size (\$m), 2016-2023 70

Figure 35: Uveitis Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2017 73

Figure 36: Uveitis Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017 74

Figure 37: Uveitis Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2017 75

Figure 38: Uveitis Therapeutics, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value (\$), 2006-2017 76

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.



No. 1101, Golden Square, 3rd Floor,
24th Main, J P Nagar, 1st Phase,
Bangalore, Karnataka, India- 560078

India: +91-8762746600

info@domain.com

-->

NAVIGATE

About Us

Reports by Region

FAQ

Privacy Policy

TERMS & CONDITIONS

CONTACT

RECENT POSTS

What is drug pipeline research?

March 20

How to use market research to bring your idea to life?

March 11

How to gain business insights using syndicated market research?

March 10

Source URL: <https://www.drugpipeline.net/gbi-research/uveitis-therapeutics-asia-pacific-markets-2023-inc-easing-prevalence-continued-uptake>

Links

[1] <https://www.drugpipeline.net/region/asia-pacific>